Opinion|Videos|November 8, 2024
Use of Targeted Agents in Generalized Myasthenia Gravis
Key Takeaways
- FcRn and complement inhibitors are used in gMG patients unresponsive to traditional therapies, offering targeted treatment options.
- Long-term management of gMG with these inhibitors requires careful integration into treatment plans for refractory cases.
Panelists discuss how they select patients for FcRn and complement inhibitor therapies, integrate these treatments into long-term management plans, monitor patients on these therapies, and approach treatment for those with inadequate disease control on traditional or targeted therapies for generalized myasthenia gravis.
Advertisement
Video content above is prompted by the following:
- In which patients and when do you typically use FcRn inhibitors and complement inhibitors?
- Where do FcRn inhibitors fit in the long-term management of gMG?
- How do you monitor patients with gMG, especially those receiving FcRn or complement inhibitor therapies?
- How do you manage gMG in patients who have inadequate disease control with traditional treatments and those currently on targeted therapies?
Advertisement
Related to this article
PridCor Therapeutics is moving its phase 2 SHIELD trial of a combination antiviral regimen toward enrollment, building on case series data showing durable symptom improvement in long COVID.
New PREVAIL trial analyses presented at the 2026 AANEM Annual Meeting showed gefurulimab reduced gMG-related hospitalizations and produced durable symptom and quality-of-life gains through one year.
FDA approves once-daily oral tavapadon for Parkinson disease, a first-in-class D1/D5 partial agonist that improves motor function and ON time, with key safety warnings.
In a discrete choice experiment, somnolence risk and short-term efficacy were the top factors driving vesicular monoamine transporter 2 inhibitor selection for tardive dyskinesia in patients aged 55 years and older.
Here's some of what is coming soon to NeurologyLive® this week.
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Approves Tavapadon for the Treatment of Parkinson Disease
2
FDA Extends Relutrigine Review, Delays PDUFA to December
3
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
4
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
5